do some people not respond to semaglutide Weight loss drug helps patients who bariatric surgery, research finds Not Losing Weight on Semaglutide?

AstraZeneca - Building a strong obesity and metabolic disease pipeline Amgen - MariTide showing promising obesity treatment potential Roche - Expanding through strategic acquisitions and obesity-focused programs Pfizer - Continuing development efforts in oral obesity medicines Structure Therapeutics - Advancing next-generation oral GLP-1 candidates Viking Therapeutics - Emerging as a major obesity treatment contender Altimmune - Developing innovative metabolic disease therapies Boehringer Ingelheim - Investing in future cardiometabolic opportunities Why is everyone chasing GLP-1

Ava Peterson, 31, Nurse (US)

Here's what it is, what the research really shows, its risks, and its legal status.

Ro and LifeMD are telehealth platforms offering GLP-1 medications for weight management and diabetes, but they differ in clinical assessment depth, medication options, and pricing models

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.